A retrospective, Observational, real-world study to compare the safety and efficacy of apixaban versus warfarin in patients with non-valvular atrial fibrillation

Trial Profile

A retrospective, Observational, real-world study to compare the safety and efficacy of apixaban versus warfarin in patients with non-valvular atrial fibrillation

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Apixaban (Primary) ; Warfarin
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Aug 2017 Results comparing the incidences of stroke/systemic embolism (S/SE) and major bleeding (MB) between standard dose/lower dose apixaban and warfarin in non-valvular atrial fibrillation patients presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 30 Aug 2017 Results of high-risk subgroups presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 25 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top